NeoadjuvantNab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX
Anticancer Research - Greece
doi 10.21873/anticanres.12692
Full Text
Open PDFAbstract
Available in full text
Date
July 1, 2018
Authors
Publisher
International Institute of Anticancer Research